A randomized, single-blind, parallel group, multiple oral dose study to evaluate the effect of a light meal on the pharmacokinetics and pharmacodynamics of aliskiren using market 300 mg tablet formulation in subjects with mild to moderate hypertension.

Trial Profile

A randomized, single-blind, parallel group, multiple oral dose study to evaluate the effect of a light meal on the pharmacokinetics and pharmacodynamics of aliskiren using market 300 mg tablet formulation in subjects with mild to moderate hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Essential hypertension
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jul 2009 Planned number of patients changed from 122 to 150 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top